Susquehanna International Group
NBIX icon

Susquehanna International Group’s Neurocrine Biosciences NBIX Stock Holding History

Susquehanna International Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Sell
87,727
-9,986
-10% -$1.32M ﹤0.01% 2898
2025
Q4 		$13.9M Buy
97,713
+93,051
+1,996% +$13.5M ﹤0.01% 2640
2025
Q3 		$654K Sell
4,662
-87,357
-95% -$11.8M ﹤0.01% 8363
2025
Q2 		$11.6M Sell
92,019
-43,276
-32% -$4.96M ﹤0.01% 2651
2025
Q1 		$15M Buy
135,295
+124,303
+1,131% +$15.7M ﹤0.01% 2048
2024
Q4 		$1.5M Sell
10,992
-61,550
-85% -$7.61M ﹤0.01% 5953
2024
Q3 		$8.36M Buy
72,542
+33,144
+84% +$4.54M ﹤0.01% 2866
2024
Q2 		$5.42M Buy
39,398
+1,424
+4% +$195K ﹤0.01% 3316
2024
Q1 		$5.24M Sell
37,974
-2,511
-6% -$343K ﹤0.01% 3566
2023
Q4 		$5.33M Sell
40,485
-94,061
-70% -$10.8M ﹤0.01% 3597
2023
Q3 		$15.1M Buy
134,546
+38,648
+40% +$4.07M ﹤0.01% 2065
2023
Q2 		$9.04M Buy
95,898
+54,587
+132% +$5.33M ﹤0.01% 2637
2023
Q1 		$4.18M Buy
41,311
+28,304
+218% +$2.95M ﹤0.01% 3717
2022
Q4 		$1.55M Sell
13,007
-6,121
-32% -$717K ﹤0.01% 5204
2022
Q3 		$2.03M Buy
19,128
+13,758
+256% +$1.4M ﹤0.01% 4903
2022
Q2 		$523K Sell
5,370
-57,535
-91% -$5.31M ﹤0.01% 8151
2022
Q1 		$5.9M Buy
62,905
+4,360
+7% +$370K ﹤0.01% 3362
2021
Q4 		$4.99M Buy
58,545
+21,006
+56% +$1.93M ﹤0.01% 3743
2021
Q3 		$3.6M Sell
37,539
-21,443
-36% -$2.03M ﹤0.01% 4578
2021
Q2 		$5.74M Buy
58,982
+46,168
+360% +$4.43M ﹤0.01% 3786
2021
Q1 		$1.25M Sell
12,814
-184,880
-94% -$19.4M ﹤0.01% 7139
2020
Q4 		$18.9M Sell
197,694
-17,843
-8% -$1.72M ﹤0.01% 1801
2020
Q3 		$20.7M Buy
215,537
+59,522
+38% +$6.89M ﹤0.01% 1448
2020
Q2 		$19M Sell
156,015
-59,220
-28% -$6.54M ﹤0.01% 1468
2020
Q1 		$18.6M Buy
215,235
+193,477
+889% +$18.9M 0.01% 1218
2019
Q4 		$2.34M Sell
21,758
-78,692
-78% -$8.24M ﹤0.01% 4066
2019
Q3 		$9.05M Sell
100,450
-9,637
-9% -$900K ﹤0.01% 2084
2019
Q2 		$9.29M Sell
110,087
-3,890
-3% -$319K ﹤0.01% 1958
2019
Q1 		$10M Buy
113,977
+106,242
+1,374% +$8.88M ﹤0.01% 1748
2018
Q4 		$552K Buy
7,735
+238
+3% +$22.8K ﹤0.01% 5833
2018
Q3 		$922K Sell
7,497
-15,149
-67% -$1.72M ﹤0.01% 5378
2018
Q2 		$2.23M Buy
+22,646
New +$2.03M ﹤0.01% 3832
2018
Q1 		– Sell
-15,992
Closed -$1.35M – 9867
2017
Q4 		$1.24M Sell
15,992
-31,938
-67% -$2.18M ﹤0.01% 4811
2017
Q3 		$2.94M Buy
47,930
+39,679
+481% +$2.09M ﹤0.01% 3262
2017
Q2 		$380K Buy
+8,251
New +$400K ﹤0.01% 7145
2016
Q2 		– Sell
-10,225
Closed -$471K – 9061
2016
Q1 		$404K Sell
10,225
-69,363
-87% -$2.75M ﹤0.01% 6768
2015
Q4 		$4.5M Buy
79,588
+5,836
+8% +$297K ﹤0.01% 2683
2015
Q3 		$2.94M Buy
73,752
+53,665
+267% +$2.59M ﹤0.01% 3537
2015
Q2 		$959K Buy
+20,087
New +$852K ﹤0.01% 6306
2015
Q1 		– Sell
-27,043
Closed -$967K – 9747
2014
Q4 		$604K Sell
27,043
-23,543
-47% -$446K ﹤0.01% 6873
2014
Q3 		$793K Sell
50,586
-28,197
-36% -$421K ﹤0.01% 6382
2014
Q2 		$1.17M Sell
78,783
-47,525
-38% -$671K ﹤0.01% 5720
2014
Q1 		$2.03M Buy
126,308
+59,059
+88% +$1.01M ﹤0.01% 4328
2013
Q4 		$629K Buy
+67,249
New +$656K ﹤0.01% 6338
2013
Q3 		– Sell
-73,469
Closed -$1.01M – 8641
2013
Q2 		$983K Buy
+73,469
New +$903K ﹤0.01% 5018

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's NBIX Position: Q1 2026 in Review

Susquehanna International Group reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q1 2026, selling an estimated $1.32M and leaving 87,727 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2898.

Susquehanna International Group first reported a position in NBIX in Q2 2013 and has held it in 45 quarters since. The position peaked at $20.7M in Q3 2020. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Susquehanna International Group held 87,727 shares of Neurocrine Biosciences worth $11.6M as of Q1 2026.
  • Susquehanna International Group sold 9,986 Neurocrine Biosciences shares in Q1 2026, an estimated $1.32M.
  • Neurocrine Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2898 holding.
  • Susquehanna International Group first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Neurocrine Biosciences position peaked at $20.7M in Q3 2020.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.